Research Grants 1999

Targeting antiapoptotic Genes TRPM-2 and Bcl-2 to improve radiation sensitivity in prostate cancer tumour cells
Dr. Kim Chi, Medical Oncologist at the Prostate Centre, Vancouver General Hospital

These genes cause cells to be resistant to radiation. Blocking these genes may dramatically improve the response of cancer cells to radiation.

Focal adhesion kinase and the invasive phenotype of human prostate cancer
Dr. Armen Aprikian, Uro-Oncologist and Associate Professor in the Department of Surgery, Urology Division, McGill University

Focal adhesion kinase is a key molecule involved in the progression of prostate cancer. Analysis of this molecule will help determine how aggressively a patient's prostate cancer is likely to behave.

Knowing this in advance of any treatment will help patients and their cancer specialists know how aggressively to treat this disease.

Hypoxia in prostate cancer - application of EF5 technologies for prognosis
Dr. Kirsten Skov, Senior Research Scientist at the BC Cancer Research Centre

Hypoxia (low oxygen) in cells makes them resistant to radiation. EF5 is a marker for hypoxia, and permits an analysis of how hypoxia prevents cancers from responding to radiation.

This may lead to improved radiation treatment and helps patients' treatment decisions as physicians will be able to assess which patients may not respond optimally to this choice of treatment.

Establishment of a PSP95 gene driven transgenic mice prostate cancer model
Dr. Jim Xuan, Assistant Professor in the Department of Surgery, University of Western Ontario 

PSP95 is a molecule, which seems to be present only in the prostate, and is secreted into the serum, similar to PSA.

This project will develop a transgenic mouse model that contains the gene for PSP95, for study, to determine the effects of this molecule on the development of prostate cancer.

Study the possible role of Selenium and Vitamin E in preventing prostate cancer and to determine the effect of reducing the presence of free radicals in patients undergoing surgery
Dr. Neil Fleshner, Assistant Professor, Department of Surgery, University of Toronto, Sunnybrook and Women's Health Science Centre
 
This work may result in nutritional therapy to prevent prostate cancer and to improve the results of treatment for those who already have prostate cancer.

Research Grants from Previous Years
Support PSA Tests


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
Prostate cancer researchers develop personalized genetic test to accurately predict recurrence risk

TORONTO, ON - November 13, 2014 – Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. More

Prostate Cancer Canada reminds men that early detection using ‘Smart Screening’ for prostate cancer

Toronto, ON – October 27, 2014 – Prostate Cancer Canada responds today to guidelines released from The Canadian Task Force on Preventive Health Care (CTFPHC) recommending that the Prostate Specific Antigen (PSA) test should be eliminated as a screening tool for prostate cancer. More


Click here for news archive